STOCKHOLM, Jan. 31, 2018 /PRNewswire/ --
The shareholders of Xspray Pharma AB (publ) are hereby
summoned to attend the extraordinary general meeting ("EGM") on
Tuesday, 20 February, 2018, at 11.00
CET at Advokatfirman Vinge's offices on Smålandsgatan 20 in
Stockholm, Sweden.
Right to participate
Those who have been recorded as shareholders in the share
register kept by Euroclear Sweden AB as per Wednesday 14 February, 2018, and who, no later than on
Wednesday 14 February, 2018, have
given notice to the company of their intent to participate at the
EGM, shall have the right to participate at the EGM. Notice to
participate shall be made in writing to the address Gunnar Asplunds
allé 32, SE-171 63 Solna or by e-mail to egm2018@xspray.com. The
notice shall contain the shareholder's name, personal identity
number or registration number and daytime telephone number and,
where applicable, the number of advisors (maximum two).
Shareholders whose shares are nominee-registered must
temporarily register their shares in their own names in the share
register kept by Euroclear Sweden AB in order to be entitled to
participate in the EGM. Such registration must be effected no later
than on 14 February, 2018 and should
be requested from the nominee well in advance.
Proxy
If a shareholder wishes to be represented by proxy, a power of
attorney shall be issued to the proxy. The power of attorney shall
be made in writing, dated and duly signed by the shareholder. If
the shareholder is a legal entity, a copy of the registration
certificate or, if no such document exists, equivalent
documentation shall be included with the notification. The
documentation shall certify the right for the person that has
signed the power of attorney to appoint a proxy for the legal
entity. To facilitate registration at the EGM, the power of
attorney shall be provided in original as well as the registration
certificate and other documents of authority shall be provided to
the company well in advance of the EGM. If the power of attorney
and the other authorization documents have not been submitted in
advance, the power of attorney in original form and other
authorization documents must be presented at the EGM. Power of
attorney forms are available at the company and on the company's
website, www.xspraypharma.com, and will be sent upon request to any
shareholder who states their postal address.
Proposed agenda
1) Opening of the meeting
2) Election of chairman of the
meeting
3) Preparation and approval of the
voting register
4) Approval of the agenda
5) Election of one or two persons
to attest the minutes
6) Determination as to whether the
meeting has been duly convened
7) The board of directors'
proposal for a resolution on a directed issue of shares
8) Closing of the meeting
Proposals
The board of directors' proposal for a resolution on a
directed issue of shares (item 7)
The board of directors proposes that the general meeting
resolves to carry out a directed issue of not more than 1,350,000
new shares, entailing an increase in the share capital of not more
than SEK 1,350,000. The resolution
shall otherwise be governed by the following terms and
conditions.
1. The right to subscribe for the new shares in the directed
issue shall, with deviation from the shareholders' pre-emption
rights, be granted to a limited number of strategic or
institutional investors which have been identified by way of a
so-called private placement procedure.
The reasons for the deviation from the shareholders' pre-emption
rights are to strengthen the institutional shareholder base of the
company, whilst in an efficiently managed and timely manner raise
capital for the development of additional drug candidates.
2. The subscription price per share shall be SEK 65. The basis for the subscription price
has been determined through a so called private placement
procedure.
3. Subscription for the newly issued shares shall take place no
later than on 23 February 2018.
Subscription shall be made on a separate subscription list. The
board shall be entitled to extend the subscription period.
4. Payment for the subscribed shares shall be made no later than
on 26 February 2018. The board shall
be entitled to delay the date of payment.
5. The new shares shall entitle to dividends from and including
the first record day for dividends following the registration of
the issue.
The board of directors, or any person appointed by the board of
directors, shall have the right to make any adjustments or
amendments of the above resolutions which may be required in
connection with the registration of such resolutions and to take
any other measure deemed necessary for the execution of the
resolutions.
Majority requirements
The general meeting's resolution under item 7 above requires
that shareholders representing not less than two thirds of both the
votes cast and of the shares represented at the meeting approve the
resolution.
Other information
When this notice to attend the EGM was issued, the total number
of shares and votes in the company was 12,356,460. The company does
not own any treasury shares. The board of directors' complete
proposal will be available at the company and on the company's
website www.xspraypharma.com, as soon as possible after the notice
has been made. Copies of the documents will be sent upon request to
any shareholder stating his/her postal address. The shareholders
are reminded of their right to request information in accordance
with Chapter 7, Section 32 of the Swedish Companies Act.
This is an unofficial translation of the Swedish original
wording. In case of differences between the English translation and
the Swedish original, the Swedish text shall prevail.
Xspray Pharma AB (publ)
The Board of
Directors
For further information, please contact:
Per Andersson, CEO, Xspray Pharma
AB (publ)
Mobile: +46(0)706-88-23-48
E-mail: per.andersson@xspray.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/xspray/r/notice-of-extraordinary-general-meeting-in-xspray-pharma-ab--publ-,c2441338
The following files are available for download:
http://mb.cision.com/Main/16033/2441338/784361.pdf
|
Notice of
extraordinary general meeting in Xspray Pharma AB (publ)
|
View original
content:http://www.prnewswire.com/news-releases/notice-of-extraordinary-general-meeting-in-xspray-pharma-ab-publ-300590917.html
SOURCE XSpray